Studies that investigate the function and expression of enzymes involved in FAO, and of the key cellular organelle in oxidative metabolism, the mitochondrion, in NAFLD models (with HIF2α deletion or pharmacological inhibition) and patients would help elucidate this. The gene discussed is EPAS1; the disease is metabolic dysfunction-associated steatotic liver disease.